Cancer Clinical Trials Testing Screening Awareness Test Drugs Patients Radiation Chemotherapy Chemo Cancer Stage 1 2 3 Diagnoses
Cancer Research ranges from epidemiology, molecular bioscience to the performance of clinical trials to evaluate and compare applications of the various cancer treatment. These applications include surgery, radiation therapy, chemotherapy and hormone therapy, and combined treatment modalities such as chemo-radiotherapy.
Simply Include The Words: "Cancer Research" In Your Tweet
Click on any of the "cancer types" below for a more in-depth view of related; blogs, articles and news:
| Lung Cancer Field Of Research |
Starting in the mid-1990s, the emphasis in clinical cancer research shifted towards therapies derived from biotechnology research, such as immunotherapy and gene therapy.
Patent litigation over human gene breast cancer testing is ending
Mutations of those genes have been linked to a higher risk of breast and ovarian cancer. The patents had given Myriad a monopoly over medical testing of those genes in a bid to detect early signs of cancer, often charging women $3,000 per test or more.
Federal Circuit to Myriad: Neither DNA Primers nor Comparing Gene Sequences ...
End of the Road: Myriad Settles Its Patent Lawsuits
Making Peace With Rivals For A Slice Of BRCA...
Social media campaign addressing prostate cancer, genetic testing
SALT LAKE CITY — A Salt Lake City-based molecular diagnostic company is hoping a social media campaign directed at men will help raise awareness about genetic testing for prostate cancer. "We regularly hear from patients that knowledge is power and ...
ProteoMedix Launching Three Clinical Validation Studies for Prostate Cancer Dx
NEW YORK (GenomeWeb) – With a CHF 1 million ($1.1 million) addition to its Series B financing round announced this week, Swiss proteomics firms ProteoMedix plans to begin clinical validation of its four-protein prostate cancer test. The company will ...
What should I know about colon cancer screening?
A screening test is used to look for a disease when a person doesn't have symptoms. (When a person has symptoms, diagnostic tests are used to find out the cause of the symptoms.) Colorectal cancer almost always develops from precancerous polyps ...
Cancer fear can impact screening uptake
Norton Healthcare first in Kentucky to offer new FDA-approved at-home colon ...
Exact Sciences Announces Norton Healthcare to Adopt Cologuard
Armune BioScience says it will launch its non-surgical prostate cancer test ...
KALAMAZOO, MI – A Kalamazoo-based bioscience company is looking to launch its inaugural product – a new, non-surgical test to detect prostate cancer --by the second quarter of this year. Armune BioScience Inc. plans to launch Apifiny by April or May.
Cancer survivor credits Mercy Health Saint Mary's $99 dollar screening program ...
WYOMING, Mich.– A cancer survivor from Wyoming is crediting Mercy Health Saint Mary's $99 screening program for saving her life. Mary Blumenstein began smoking at just 16 years old. Despite caring for cancer patients as a nurse and losing her father to ...
Women, providers unhappy with cervical cancer screening changes
Many female patients and health-care providers are unsure about the changes in cervical cancer screening procedure, a survey conducted by the National Association for Nurse Practitioners in Women's Health and HealthyWomen indicates. "The data in this ...
Ask the Doctor: Positive HPV test result doesn't necessarily mean cancer
Cervical Cancer Prevention Week: Everything you need to know about smear tests
Cervical cancer and HPV— reduce your risk
Myriad Genetics ends feud over breast cancer screening patent
Genetic Literacy Project
Myriad's lucrative monopoly on testing for mutations in two genes linked to an increased risk of breast and ovarian cancer ended in 2013, when the Supreme Court ruled that human genes were not eligible for patents because they were products of nature.
Myriad Throws in the Towel
Medicare Advisers to Focus on Cancer Tests
Roll Call (blog)
At the March meeting, the advisers' discussion is intended to help CMS shape decisions “about the extent to which it may wish to use existing evidence as the basis for any future determinations about coverage for tests that estimate cancer prognosis.”.
Myriad Genetics Ending Patent Dispute on Breast Cancer Risk Testing
New York Times
Myriad Genetics has essentially given up trying to stop other companies from offering tests for increased risk of breast cancer, ending a dispute that was the subject of a landmark Supreme Court ruling that human genes cannot be patented. The company ...